RWM
BBIO icon

Rialto Wealth Management’s BridgeBio Pharma BBIO Stock Holding History

Rialto Wealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34K Buy
18
+9
+100% +$630 ﹤0.01% 1258
2026
Q1 		$669 Sell
9
-106
-92% -$7.68K ﹤0.01% 1256
2025
Q4 		$8.8K Buy
115
+2
+2% +$131 ﹤0.01% 459
2025
Q3 		$5.87K Sell
113
-104
-48% -$5.07K ﹤0.01% 469
2025
Q2 		$9.37K Sell
217
-212
-49% -$7.71K ﹤0.01% 425
2025
Q1 		$14.8K Hold
429
– – ﹤0.01% 372
2024
Q4 		$11.8K Buy
+429
New +$11.1K ﹤0.01% 374

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Rialto Wealth Management's BBIO Position: Q2 2026 in Review

Rialto Wealth Management increased its BridgeBio Pharma (BBIO) stake by 100% in Q2 2026, buying an estimated $630 and bringing the position to 18 shares worth $1.34K. The position accounts for ﹤0.01% of the portfolio, ranked #1258.

Rialto Wealth Management first reported a position in BBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $14.8K in Q1 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Rialto Wealth Management held 18 shares of BridgeBio Pharma worth $1.34K as of Q2 2026.
  • Rialto Wealth Management bought 9 BridgeBio Pharma shares in Q2 2026, an estimated $630.
  • BridgeBio Pharma made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1258 holding.
  • Rialto Wealth Management first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 7 quarters since.
  • Rialto Wealth Management's BridgeBio Pharma position peaked at $14.8K in Q1 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.